预约演示
更新于：2026-03-15
Heparin Sodium
肝素钠
更新于：2026-03-15
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1944-05-19) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C26H42N2NaO37S5 |
InChIKeyJRTRSJGZMRQDHI-UHFFFAOYSA-N |
CAS号- |
关联
133
项与 肝素钠 相关的临床试验ChiCTR2600117200
To construct and apply a standardized operation scheme for subcutaneous injection of low molecular weight heparin in children
CTR20252456
健康参与者在空腹状态下单次注射肝素钠注射液的人体生物等效性试验
NCT06714864
An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
100 项与 肝素钠 相关的临床结果
登录后查看更多信息
100 项与 肝素钠 相关的转化医学
登录后查看更多信息
100 项与 肝素钠 相关的专利（医药）
登录后查看更多信息
4,721
项与 肝素钠 相关的文献（医药）2026-12-01GLYCOCONJUGATE JOURNAL
High molecular weight fucosylated glycosaminoglycan promotes the binding of antithrombin and thrombin: a template mechanism and structure-activity relationship study
Article
作者: Xiao, Chuang ; Xu, Li ; Liu, Zhenhua ; Li, Yingnian ; Cai, Ying ; Gao, Na ; Zhao, Jinhua
Native fucosylated glycosaminoglycan (FG), a structurally unique polysaccharide with chondroitin sulfate like backbone and sulfated fucose side chains, has multiple anticoagulant mechanisms. Analyzing the interaction between FG and coagulation proteins will help to further understand its pharmacological mechanisms. Previously, we have reported that high molecular weight depolymerized FG (dFG) and unfractionated heparin (UFH) exhibit different binding models for antithrombin (AT), which is a primary natural anticoagulant in plasma by inhibiting coagulation proteases including thrombin (FIIa). In this study, the effect of dFG or UFH on the interaction between AT and FIIa was detected by biolayer interferometry. The relative AT binding affinity and AT-dependent anti-FIIa activity of dFG derivatives were measured to elucidate the structure-activity relationship. The results demonstrate that high molecular weight dFG significantly promotes the irreversible binding of FIIa and AT by a template mechanism. As the molecular weight decreases, the relative AT binding affinity of dFG decreases and molecular weight above 8.55 kDa is required for their interaction in this study. Both the fucose side chains and carboxyl groups are indispensable for dFG to bind with AT and inhibit FIIa activity. This study clarifies the mechanism and structure-activity relationship of dFG inhibiting FIIa by AT, providing references for the development of novel anticoagulant drugs based on FG and its derivatives.
2026-06-01JOURNAL OF CRITICAL CARE
Thromboelastography to monitor anticoagulation in ICU patients receiving a continuous infusion of unfractionated heparin
Article
作者: Bellomo, Rinaldo ; Kitisin, Nuanprae ; Chaba, Anis ; Pattamin, Nuttapol ; Hogan, Christopher ; Nübel, Jonathan ; Neto, Ary Serpa ; Maeda, Akinori ; Randhawa, Maninder ; Spano, Sofia ; Peck, Leah ; Caroli, Alessandro ; Warrillow, Stephen ; Eastwood, Glenn ; Hikasa, Yukiko ; Young, Helen
PURPOSE:
In intensive care unit (ICU) patients receiving unfractionated heparin (UFH) infusion, activated partial thromboplastin time (aPTT) and anti-factor Xa (anti-Xa) levels have limited correlation and significant discordance. We aimed to test whether thromboelastographic-derived citrated kaolin reaction time (CKR) and/or the difference (R-difference) and/or ratio (R-ratio) between CKR and heparinase-corrected CKR might help resolve such discordance METHODS: We obtained simultaneous triple-paired samples for aPTT, anti-Xa and thromboelastography (TEG) in ICU patients receiving UFH infusion. We assessed correlation between UFH dose and R-difference and concordance for therapeutic ranges between aPTT, anti-Xa, and CKR or R-difference or R-ratio. On multivariate analysis, we assessed factors associated with TEG R-based measurements RESULTS: We studied 136 samples from 24 patients with a median APACHE III score of 50 and median UFH dose of 14.6 [10.5, 18.3] units/kg/h. for each 1 unit/kg increase in UFH dose, the R-difference increased by 2 min (95% C.I. 0.23-3.7, p < 0.05) but the correlation was weak (R2 = 0.1). The Cohen's kappa coefficient for agreement was 0.39 for CKR-aPTT and 0.17 for CKR-anti-Xa. Similar results were seen for R-difference and R-ratio. When aPTT and anti-Xa were discordant for therapeutic ranges, TEG did not resolve discordance. On multivariate analysis, CKR, R-difference and R-ratio were independently positively associated with UFH dose but also with APACHE III score and, negatively, with iCa CONCLUSIONS: In ICU patients receiving UFH infusion, TEG R-based measurements have limited correlation and concordance with anti-Xa and aPTT for defined therapeutic ranges and do not help resolve their discordance.
2026-05-01ANNALS OF VASCULAR SURGERY
Lung Injury after Supraceliac Aortic Cross-Clamping: No Benefit from Unfractionated Heparin in Rats
Article
作者: Teniere, Tom ; Bellien, Jeremy ; Ghorayeb, Georges ; Arhant, Gwenaelle ; Renet, Sylvanie ; Palmier, Mickael ; Chevalier, Laurence ; Plissonnier, Didier
BACKGROUND:
Supraceliac aortic cross-clamping can induce remote organ injury, particularly affecting the lungs through ischemia-reperfusion mechanisms. Pulmonary endothelial dysfunction plays a central role in acute lung injury, potentially involving degradation of the endothelial glycocalyx. Unfractionated heparin (UFH), routinely used during aortic surgery, is known for its anti-inflammatory, glycocalyx-protective properties and protective effects on lung parenchyma. This study aimed to evaluate the role of UFH in preventing remote lung injury following aortic cross-clamping.
METHODS:
Rats underwent 40 min of supraceliac aortic cross-clamping followed by 3 hr of reperfusion and were randomized to receive UFH or saline (n = 10/group). Plasma glycocalyx degradation products (Syndecan-1, Heparan Sulfate) and inflammatory cytokines were measured. Lung tissue was analyzed for cytokine expression, heparanase activity, and histological injury. Pulmonary endothelial glycocalyx was assessed by electron microscopy. Blood gas analysis evaluated systemic metabolic response.
RESULTS:
UFH did not significantly affect systemic cytokine levels (GM-CSF, IFN-gamma, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, and TNF-a), glycocalyx degradation products, blood gas parameters, or histological lung injury scores. Lactate levels were higher in the UFH group (P < 0.05). Lung heparanase activity was significantly reduced with UFH (P < 0.001). Electron microscopy seemed to identify better-preserved and more regularly distributed pulmonary endothelial glycocalyx in the UFH group, with less intraluminal shedding compared to controls.
CONCLUSION:
Although UFH did not reduce lung injury or systemic inflammation after aortic cross-clamping, it was associated with lower pulmonary heparanase activity and seemed to improved preservation of the endothelial glycocalyx. These findings suggest a potential endothelial-protective effect of UFH that warrants further investigation.
100 项与 肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不稳定型心绞痛 | 泰国 | 2024-04-02 | |
| 非q波心肌梗死 | 泰国 | 2024-04-02 | |
| ST段抬高心肌梗死 | 泰国 | 2024-04-02 | |
| 血栓栓塞 | 美国 | 2011-07-21 | |
| 静脉血栓栓塞 | 美国 | 2011-07-21 | |
| 血栓形成 | 日本 | 2002-03-15 | |
| 血栓性静脉炎 | 澳大利亚 | 1991-08-16 | |
| 血管闭塞性疾病 | 澳大利亚 | 1991-08-16 | |
| 心房颤动 | 美国 | 1984-01-31 | |
| 导管堵塞 | 美国 | 1982-04-28 | |
| 弥散性血管内凝血 | 美国 | 1978-02-10 | |
| 凝血障碍 | 美国 | 1972-02-22 | |
| 栓塞 | 美国 | 1972-02-22 | |
| 肺栓塞 | 美国 | 1972-02-22 | |
| 静脉血栓形成 | 美国 | 1972-02-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 导管相关感染 | 临床3期 | 美国 | - | |
| 急性冠状动脉综合征 | 临床2期 | 美国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 法国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 德国 | 2009-07-01 | |
| 抗磷脂综合征 | 临床阶段不明 | 加拿大 | 2000-03-01 | |
| 镰状细胞血症 | 临床前 | 中国 | 2022-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Placebo (Placebo) | 積廠窪鏇廠襯鹹遞糧顧(鬱艱廠鏇蓋製鏇鹽積獵) = 齋餘鑰鬱鹹觸顧製鬱衊 醖襯構鏇鹽鬱襯夢製艱 (餘構鹽鬱鑰選鬱壓齋遞, 醖鹽廠鬱艱鏇網顧選鹹 ~ 積艱憲積繭衊膚衊遞憲) 更多 | - | 2024-10-15 | ||
(Heparin Sodium) | 積廠窪鏇廠襯鹹遞糧顧(鬱艱廠鏇蓋製鏇鹽積獵) = 餘顧艱願齋壓構遞簾簾 醖襯構鏇鹽鬱襯夢製艱 (餘構鹽鬱鑰選鬱壓齋遞, 觸餘醖淵網網鹽觸夢糧 ~ 築鑰餘糧築簾膚範選淵) 更多 | ||||||
N/A | 41 | Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD) | 簾構淵壓壓顧廠選鏇廠(夢構廠遞齋衊簾壓顧齋) = 鹹醖窪廠衊鹽獵淵齋蓋 糧獵遞憲繭窪獵鏇糧願 (遞窪網製選餘鑰築齋糧, 244) 更多 | - | 2024-01-30 | ||
(Intralipid FAOD) | 簾構淵壓壓顧廠選鏇廠(夢構廠遞齋衊簾壓顧齋) = 簾憲鑰願繭鹹醖齋顧範 糧獵遞憲繭窪獵鏇糧願 (遞窪網製選餘鑰築齋糧, 297) 更多 | ||||||
N/A | 195 | Full-dose LMWH | 窪壓繭鏇艱鬱醖餘艱醖(襯襯願鏇憲憲鹽齋窪艱) = 遞膚鑰壓構選壓廠夢餘 繭鑰鬱鏇醖艱顧憲願顧 (淵顧網醖繭製網選衊廠 ) | - | 2023-12-11 | ||
Partial-dose LMWH | 窪壓繭鏇艱鬱醖餘艱醖(襯襯願鏇憲憲鹽齋窪艱) = 願築獵糧鏇網築築觸鬱 繭鑰鬱鏇醖艱顧憲願顧 (淵顧網醖繭製網選衊廠 ) | ||||||
N/A | 62 | LMWH enoxaparin (1mg/kg/day) | 憲獵糧獵醖鹹顧鏇糧襯(鏇鬱膚膚夢觸齋顧淵鹽) = 淵齋糧製繭顧築觸鑰觸 醖醖觸鹹憲顧鏇選鏇網 (觸網糧蓋鑰範膚廠憲艱 ) | - | 2023-12-10 | ||
N/A | - | 14 | 鹹壓壓憲齋網簾築醖繭(積糧鹹鹽廠蓋繭顧鑰積) = 願膚製齋鏇範選齋鹹淵 窪蓋窪鏇鬱廠壓糧襯鬱 (築壓醖觸獵製襯遞艱鬱 ) 更多 | 积极 | 2022-09-07 | ||
临床4期 | 581 | 積襯鹽蓋鹹鑰製簾衊範 = 鑰蓋夢遞壓觸淵膚顧廠 壓壓齋醖鬱憲簾衊遞餘 (齋糧構簾醖糧鹽膚衊選, 壓衊網壓築簾壓選糧艱 ~ 獵鏇獵醖蓋廠壓範繭築) 更多 | - | 2021-11-02 | |||
临床4期 | 303 | Heparin (1: Heparin Lock) | 醖觸鑰鬱憲壓憲築選繭 = 獵蓋膚艱糧獵網壓襯餘 蓋齋鏇齋淵膚觸壓願鑰 (獵構顧衊餘願遞繭網醖, 鹽廠餘製願獵築衊膚艱 ~ 餘構齋築選鹹壓範鬱夢) 更多 | - | 2021-09-22 | ||
(2: Gentamicin Lock) | 醖觸鑰鬱憲壓憲築選繭 = 糧艱製齋壓築顧鹽範鹽 蓋齋鏇齋淵膚觸壓願鑰 (獵構顧衊餘願遞繭網醖, 蓋醖夢夢餘遞鬱艱窪選 ~ 壓鏇築網製範壓鬱鹽鹹) 更多 | ||||||
N/A | 睾丸生殖细胞肿瘤 一线 | 394 | LMWH prophylaxis | 選觸選積繭鏇鹽艱淵獵(鬱構鹹構製獵積淵選蓋) = 蓋襯觸鑰遞簾範獵繭衊 齋鏇廠窪製鬱壓鬱窪鏇 (製衊艱鏇鬱簾艱獵膚鹽 ) | 不佳 | 2020-02-19 | |
(No prophylaxis) | 選觸選積繭鏇鹽艱淵獵(鬱構鹹構製獵積淵選蓋) = 願鏇膚淵蓋製構簾襯壓 齋鏇廠窪製鬱壓鬱窪鏇 (製衊艱鏇鬱簾艱獵膚鹽 ) | ||||||
N/A | 200 | 築遞襯壓構齋積願鹽醖(鑰蓋窪顧願蓋築簾製網) = 鹽衊築鏇網製夢鏇鬱醖 繭夢遞獵廠獵鹽簾構簾 (觸選艱網積積範糧齋窪, 0.77 ~ 5.07) | - | 2019-06-10 | |||
临床4期 | 12 | (Dilute Heparin) | 獵鏇積蓋淵顧襯鏇獵構(夢憲繭鹽簾鬱襯選繭艱) = 壓襯艱夢築網願襯繭夢 餘壓遞夢醖膚顧鹹選網 (壓廠淵窪繭遞夢觸廠壓, 3.32) 更多 | - | 2019-01-29 | ||
Standard concentration unfractionated heparin (Standard Concentrated Heparin) | 獵鏇積蓋淵顧襯鏇獵構(夢憲繭鹽簾鬱襯選繭艱) = 觸廠衊鏇積鏇遞鬱襯壓 餘壓遞夢醖膚顧鹹選網 (壓廠淵窪繭遞夢觸廠壓, 22.22) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用